TMIGD2 Human

IGPR-1, IGPR1,TMIGD2, Transmembrane and immunoglobulin domain-containing protein 2 isoform1, CD28 homolog, CD28H, Immunoglobulin and proline-rich receptor 1.

TMIGD2 Human Recombinant is a single, glycosylated, polypeptide chain (23-150 a.a) containing a total of 361 amino acids and having a molecular mass of 40.1 kDa.
TMIGD2 is fused to a 233 a.a hIgG -Tag at C-terminus and is purified by proprietary chromatographic techniques.

HEK293 Cells.

The TMIGD2 solution (1mg/ml) contains 10% Glycerol and Phosphate-Buffered Saline (pH 7.4).

Store at 4°C if entire vial will be used within 2-4 weeks.
Store, frozen at -20°C for longer periods of time.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Avoid multiple freeze-thaw cycles.

Greater than 95.0% as determined by SDS-PAGE.

SDS

Transmembrane and immunoglobulin domain-containing protein 2 (TMIGD2) has recently garnered attention as a potentially significant player in immune modulation and cellular interactions. In its human recombinant form, TMIGD2 emerges as a valuable tool for unraveling its molecular intricacies and exploring its potential applications in immunotherapy and beyond. This research embarks on an exploratory journey to unveil the diverse roles of TMIGD2 Human Recombinant, shedding light on its structural attributes, cellular functions, and implications in immune regulation. By delving into the properties of TMIGD2, scientists aim to deepen our understanding of immune responses and open new avenues for therapeutic interventions.

 Structural Insights into TMIGD2 Human Recombinant:

TMIGD2, a transmembrane protein with immunoglobulin-like domains, presents a unique structural configuration essential for its cellular interactions. The human recombinant form provides a controlled system for exploring the three-dimensional intricacies of TMIGD2, offering insights into its binding affinities and conformational dynamics. Understanding its structure is fundamental for deciphering how TMIGD2 engages with cellular partners and modulates immune responses.

 Cellular Functions in Immune Modulation:

The primary function of TMIGD2 is implicated in immune modulation, with its expression observed in immune cells such as T cells and natural killer (NK) cells. TMIGD2 Human Recombinant studies have started to uncover its potential role in regulating immune responses. Elucidating its cellular functions provides insights into how TMIGD2 contributes to the dynamic orchestration of immune reactions, including T cell activation and cytotoxicity.

 Implications in Cancer Immunotherapy:

Given its expression in immune cells, TMIGD2 has become a subject of interest in the context of cancer immunotherapy. Preliminary studies involving TMIGD2 Human Recombinant suggest its involvement in tumor immune evasion mechanisms and its potential as a target for enhancing antitumor immune responses. Understanding the interplay between TMIGD2 and the tumor microenvironment holds promise for the development of novel immunotherapeutic strategies.

TMIGD2 in Autoimmune Disorders:

Conversely, dysregulation of TMIGD2 may contribute to autoimmune disorders, where the immune system mistakenly targets the body's own tissues. Investigations into TMIGD2 Human Recombinant may shed light on its role in immune tolerance and the prevention of excessive immune reactions. Deciphering the nuances of TMIGD2's functions provides potential insights for therapeutic interventions in autoimmune conditions.

 Challenges and Future Directions:

While the potential of TMIGD2 Human Recombinant in immune modulation is promising, challenges persist. Fine-tuning its applications, understanding its interactions with various immune cell types, and deciphering the context-dependent nature of its functions are critical considerations for translational success. Additionally, exploring the potential dual role of TMIGD2 in cancer immunity and autoimmune disorders poses a challenge in the pursuit of targeted therapeutic strategies.

TMIGD2 Human Recombinant emerges as a promising protagonist in the narrative of immune modulation, offering a controlled platform for scientific exploration. Its structural insights, cellular functions, and implications in immune regulation position it as a key player in the evolving landscape of immunotherapy and immune-related disorders. As researchers continue to unravel the molecular intricacies of TMIGD2, they not only deepen our understanding of immune responses but also pave the way for transformative advancements in cancer immunotherapy and autoimmune disease therapeutics, shaping the future of precision medicine and immunomodulatory interventions.